DK3154528T3 - Sprøjtetørrede sammensætninger med forskellige opløsningsprofiler og fremgangsmåder til fremstilling deraf - Google Patents

Sprøjtetørrede sammensætninger med forskellige opløsningsprofiler og fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK3154528T3
DK3154528T3 DK15807576.2T DK15807576T DK3154528T3 DK 3154528 T3 DK3154528 T3 DK 3154528T3 DK 15807576 T DK15807576 T DK 15807576T DK 3154528 T3 DK3154528 T3 DK 3154528T3
Authority
DK
Denmark
Prior art keywords
preparation
methods
spray dried
dissolution profiles
different dissolution
Prior art date
Application number
DK15807576.2T
Other languages
English (en)
Inventor
Joseph M Davis
Robert C Cuca
Edward J Beasley
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Application granted granted Critical
Publication of DK3154528T3 publication Critical patent/DK3154528T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15807576.2T 2014-06-11 2015-05-27 Sprøjtetørrede sammensætninger med forskellige opløsningsprofiler og fremgangsmåder til fremstilling deraf DK3154528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462010691P 2014-06-11 2014-06-11
PCT/US2015/032603 WO2015191282A1 (en) 2014-06-11 2015-05-27 Spray dried compositions having different dissolution profiles and processes for their preparation

Publications (1)

Publication Number Publication Date
DK3154528T3 true DK3154528T3 (da) 2023-04-24

Family

ID=54834103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15807576.2T DK3154528T3 (da) 2014-06-11 2015-05-27 Sprøjtetørrede sammensætninger med forskellige opløsningsprofiler og fremgangsmåder til fremstilling deraf

Country Status (12)

Country Link
US (1) US11464741B2 (da)
EP (2) EP3154528B1 (da)
JP (1) JP6636952B2 (da)
AU (1) AU2015275098B2 (da)
CA (1) CA2950734C (da)
DK (1) DK3154528T3 (da)
ES (1) ES2942619T3 (da)
HU (1) HUE061928T2 (da)
MX (1) MX387735B (da)
PL (1) PL3154528T3 (da)
PT (1) PT3154528T (da)
WO (1) WO2015191282A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009927A1 (en) 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc MIXTURE COMPOSITIONS FOR ORAL ADMINISTRATION AS POWDER AND / OR SUSPENSION WITH RAPID DISSOLUTION
CN118399020B (zh) * 2024-07-01 2024-09-24 浙江功能膜材料创新中心有限公司 一种电池隔膜及其制备方法、二次电池和用电装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111077B1 (da) * 1970-08-05 1976-04-08
US4661521A (en) 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
US4904477A (en) 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
US5739139A (en) * 1996-06-20 1998-04-14 Mcneil-Ppc, Inc. Acetaminophen and dimenhydrinate analgesics
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
EP1158957A4 (en) 1999-02-24 2004-12-15 Dong Wha Pharm Ind Co Ltd LIQUID SUPPOSITORIAL COMPOSITION OF DICLOFENAC SODIUM
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
NZ516083A (en) 1999-05-27 2003-08-29 Acusphere Inc Porous drug matrices and methods of manufacture thereof
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
US20030161879A1 (en) 1999-06-29 2003-08-28 Shinji Ohmori Tablets quickly disintegrating in mouth
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
ATE367802T1 (de) 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
KR100507771B1 (ko) 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
EP1661556A4 (en) 2003-08-20 2010-05-19 Ajinomoto Kk MEDICAL PREPARATION WITH IMPROVED RESOLUTION CHARACTERISTICS
TWI335227B (en) * 2004-02-25 2011-01-01 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
JP5147239B2 (ja) 2004-09-29 2013-02-20 三栄源エフ・エフ・アイ株式会社 コエンザイムｑ１０含有乳化組成物
EP1845803B1 (en) 2005-02-03 2014-04-30 Firmenich SA Method for the prepration of spray-dried compositions and their uses
CN101262860A (zh) 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2039353B1 (en) 2006-06-22 2018-12-05 Kaneka Corporation Reduced coenzyme q10-containing composition and method for producing the same
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
JP5244790B2 (ja) * 2007-04-16 2013-07-24 株式会社カネカ 還元型補酵素ｑ１０含有粒子状組成物及びその製造方法
GB0811024D0 (en) * 2008-06-17 2008-07-23 E Therapeutics Plc Sustained release treatment of depression
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents

Also Published As

Publication number Publication date
PL3154528T3 (pl) 2023-07-10
JP6636952B2 (ja) 2020-01-29
US11464741B2 (en) 2022-10-11
AU2015275098B2 (en) 2018-12-06
WO2015191282A1 (en) 2015-12-17
EP4223286A3 (en) 2023-08-16
EP3154528B1 (en) 2023-04-05
CA2950734A1 (en) 2015-12-17
JP2017521368A (ja) 2017-08-03
ES2942619T3 (es) 2023-06-05
EP4223286A2 (en) 2023-08-09
HUE061928T2 (hu) 2023-09-28
MX2016015528A (es) 2017-04-25
CA2950734C (en) 2022-07-26
US20150359743A1 (en) 2015-12-17
MX387735B (es) 2025-03-11
EP3154528A1 (en) 2017-04-19
EP3154528A4 (en) 2017-12-20
AU2015275098A1 (en) 2016-12-15
PT3154528T (pt) 2023-06-22

Similar Documents

Publication Publication Date Title
KR20180084891A (ko) 구조 조성물 및 방법
DK3386484T3 (da) Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3145493T3 (da) Fremgangsmåder og sammensætninger vedrørende exosomer
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3108009T3 (da) Fremgangsmåder og sammensætninger til DNA-profilering
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
IL247292A0 (en) Antireflective coating compositions and processes thereof
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3310340T3 (da) Formulering med høj koncentration
IL256374B (en) Long-acting coagulation factors and methods of producing same
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3357343T3 (da) Fedtsammensætning og fremgangsmåde til fremstilling heraf
DK3212166T3 (da) Varme-steriliseret formulering omfattende chitosan og fremgangsmåde til fremstilling deraf
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
LT3347356T (lt) Tricikliniai sulieti piridin-2-ono dariniai ir jų naudojimas kaip brd4 inhibitorių